Table 2.
Biochemical and clinical outcomes and treatment information in all patients.
| Total study cohort (N = 436) | ||
|---|---|---|
| Individuals with Crohn’s disease (N = 214) | Individuals with ulcerative colitis (N = 222) | |
| Week 30 FCP (µg/g) | ||
| N | 88 | 82 |
| Median (IQR) | 292.5 (86.3, 1005.0) | 138.5 (41.5, 425.0) |
| Remitters N (%) | 43 (48.9%) | 54 (65.9%) |
| Week 30 CRP (mg/l) | ||
| N | 133 | 115 |
| Median (IQR) | 3.0 (1.0, 6.0) | 2.0 (1.0, 5.0) |
| Remitters N (%) | 89 (66.9%) | 79 (68.7%) |
| Week 30 disease score | HBI | PMS |
| N | 122 | 103 |
| Median (IQR) | 4.0 (2.0, 6.0) | 1.0 (0.0, 3.0) |
| Remitters N (%) | 74 (60.7%) | 75 (72.8%) |
CRP, C-reactive protein; FCP, faecal calprotectin; HBI, Harvey-Bradshaw Index; PMS, Partial Mayo Score.
Normalization defined as week 30 FCP <250 μg/g, CRP <5 mg/l, HBI <5, PMS <3.